Jeff Goater News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kenai Therapeutics a biotechnology company leveraging induced pluripotent stem cell iPSC technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders today announced an 82 million Series A financing coled by Alaska Permanent Fund Corporation Cure Ventures and The Column Group with participation from Euclidean Capital and Saisei Ventures.

AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today announced the appointment

Biopharma veteran Ben Hickey appointed to Board of Directors

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Editas Medicine  James Mullen takes over as CEO from Feb. 15. Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon—later snapped up by Thermo Fisher—and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo...